mail
editor@ajptr.com
whatsapp
9409046853
logo

American Journal of PharmTech Research

Published

Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles

Published in October 2019 Issue 5 (Vol. 9, Issue 5, 2019)

Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles - Issue cover

Abstract

Tuberculosis is a ubiquitous, highly contagious chronic granulamatous communicable bacterial infectious disease caused by Mycobacterium tuberculosis and other species of same genera. “Rifabutin” which is useful in the management of tuberculosis. Formulated Rifabutin in the form of solid lipid nanoparticle evaluated for their efficacy ex-vivo by checking for various interactions. Thus, physiological parameters like cellular uptake, MTT cytotoxicity assay and hemolytic toxicity of rifabutin  loaded mannosylated solid lipid nanoparticles are determined and compared. The present work establishes the suitability of rifabutin loaded mannosylated solid lipid nanoparticles as a delivery system.

Authors (3)

Download Article

PDF

Best for printing and citation

File size: 0.0 MB
Format: PDF

Download Article

PDF

Best for printing and citation

File size: 0.0 MB
Format: PDF

Article Information

Article ID:
AJPTR95002
Paper ID:
AJPTR-01-001216
Published Date:
2019-10-01

Article Impact

Views:5,499
Downloads:1,335
scite_
PlumX Metrics Badge

How to Cite

Patel & K., G. & Sharma (2019). Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles. American Journal of PharmTech Research, 9(5), xx-xx. DOI:https://doi.org/10.46624/ajptr.2019.v9.i5.002

Article Actions

Whatsapp